Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, 3000, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, 3010, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, 3010, Australia.
Curr Opin Pharmacol. 2020 Aug;53:91-97. doi: 10.1016/j.coph.2020.07.002. Epub 2020 Aug 24.
Adoptive cellular therapy involves the ex vivo expansion of immune cells, conventionally T cells, before reinfusion back to the patient. Variations in adoptive cellular therapy include transduction of a patient's T cells with either a transgenic T cell receptor or chimeric antigen receptor (CAR) to recognize a defined tumor antigen. Given that adenosine is a major axis of immunosuppression of T cells, particularly in hypoxic tumor microenvironments, therapeutics targeting this pathway are currently being assessed for their potential to enhance adoptive T cell therapies. The use of gene-editing technology, commonly used in tandem with CAR and transgenic T cell receptor (TCR) based adoptive cellular therapy, offers further opportunities to specifically modulate responses to adenosine. This review will discuss recent advances in targeting the adenosine pathway for enhancing the effectiveness of adoptive cellular therapy in the treatment of solid cancers.
过继性细胞疗法包括在将免疫细胞（通常是 T 细胞）重新注入患者体内之前，进行体外扩增。过继性细胞疗法的变化包括转导患者的 T 细胞，使用转基因 T 细胞受体或嵌合抗原受体（CAR）来识别特定的肿瘤抗原。鉴于腺苷是 T 细胞免疫抑制的主要途径，特别是在缺氧的肿瘤微环境中，目前正在评估针对该途径的治疗方法，以评估其增强过继性 T 细胞疗法的潜力。基因编辑技术的使用，通常与基于 CAR 和转基因 T 细胞受体（TCR）的过继性细胞疗法联合使用，为专门调节对腺苷的反应提供了更多机会。本综述将讨论靶向腺苷途径的最新进展，以提高过继性细胞疗法在治疗实体瘤中的有效性。
